AlzeCure’s CEO Martin Jönsson at Redeye, April 11, 2024 (Swedish)
CEO Martin Jönsson presenting at Finwire, April 10, 2024 (Swedish)
About Professor Jan Lundberg, who is proposed for election to the company’s Board of Directors
– from senior positions in global pharmaceutical companies, including global head of research at Astra and AstraZeneca and global R&D at Eli Lilly
AlzeCure’s CEO Martin Jönsson at Redeye’s event on Alzheimer’s, March 21, 2024 (Swedish)
Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event – Alzheimer’s around highly current gamma-secretase modulators
Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure
Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event
Expert Event – Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together with professor Henrik Zetterberg”
AlzeCure at Redeye Life Science Day 2023 on November 23, 2023
AlzeCure at Redeye Neurology Theme Event October 11, 2023
AlzeCure Pharma present at Finwire September 5, 2023
AlzeCure Pharma present at Finwire – CMO Märta Segerdahl
AlzeCure Pharma present at Finwire – CSO Johan Sandin
AlzeCure Pharma’s CEO Martin Jönsson – Infocus interview at Redeye Growth Day on June 1th , 2023
AlzeCure Pharma – Capital Market Day May 17th, 2023
AlzeCure presents at Redeye Growth Day on June 1st, 2023
Alzheimer’s disease; Challenges & Opportunities with Professor Bengt Winblad Karolinska Institutet
Presentation of the development of AlzeCure’s Alzheimer project Alzstatin and NeuroRestore
Alzstatin – A preventive treatment against Alzheimer’s – Background & Evolution with Johan Sandin
NeuroRestore: Background & data supporting disease modifying effects with Pontus Forsell
Interview at Finwire with CEO Martin Jönsson
CEO Martin Jönsson at Redeye April 12, 2023 (Swedish)
CEO Martin Jönsson participated in Redeye Alzheimer Seminar(Swedish)
Sitdown at Finwire with CEO Martin Jönsson(Swedish)
Watch the interview at Redeye with CEO Martin Jönsson and Märta Segerdahl MD, PhD. Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440. January 31, 2023 (Swedish)
CEO Martin Jönsson’s interview with Redeye, the outcome of the issue and milestones in 2023, 9 January (Swedish)
Chief Scientific Officer Johan Sandin has participated in interview with Erik Penser Bank, December 13, 2022
(The presentation will be held in Swedish)
Interview at Finwire news with CEO Martin Jönsson, December 12, 2022
(The presentation will be held in Swedish)
CEO Martin Jönsson presents AlzeCure at BioStock, December 5, 2022
AlzeCure’s CEO Martin Jönsson presents at BioStock in connection with a new share issue, December 5, 2022
CEO Martin Jönsson is interviewed at Redeye Life Sciences Day, November 24, 2022
Erik Penser – CEO Martin Jönsson gives a company presentation with regards to the ongoing rights issue December 6–20, 2022
Erik Penser – Interview with AlzeCure’s CEO Martin Jönsson regarding the ongoing rights issue December 6–20, 2022
Preclinical characterization of ACD856. Scientific presentation at the Ctad conference nov 29- 2dec, 2022
AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the Ctad conference nov 29- 2dec, 2022
Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the Ctad conference nov 29- 2dec, 2022
Martin Jönsson presented at Life Science Investor Conference, November 23, 2022
Carlsquare’s Investor Day on Life science, Nov. 17, 2022 (English)
Aktiespararna’s event with AlzeCure on November 16, 2022
CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022
CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.
Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish) September 12, 2022
Watch the interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress, September 1, 2022 (Swedish)
Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish) July 1, 2022
AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish) June 23, 2022
AlzeCure at Redeye Growth Day June 2, 2022
CEO Martin Jönsson Presenting at Redeye Growth Day May 23, 2022
AlzeCure – Alzheimer event at Redeye 3 May, 2022 (Swedish)
Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future. March 14, 2022 (Swedish)
CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue. March 14, 2022
CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies. (Swedish) March 14, 2022
Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue. (Swedish)
See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue. (Swedish)
AlzeCure – New presentation at Penser. (Swedish)
CEO Martin Jönsson presents AlzeCure’s development, plans and success.
Latest newsflow February 3. 2022 (Swedish)
CEO Martin Jönsson presents at Aktiespararna January 31, 2022 (Swedish)
AlzeCure Pharma – Kapitalmarknadsdag, Januari 18 2022
AlzeCure medverkar på Erik Penser Banks temadag Life Science, December 2, 2021
Follow us – Stay updated
AlzeCure Pharma – Redeye Life Science Day, November 11, 2021
AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.
Alzecure presents at Healthcare Innovation Summit, October 7, 2021
Alzecure Pharma – Naventus Life Science Summit, September 29, 2021
Aktiespararna intervjuar VD Martin Jönsson – senaste kvartalsrapporten och framtidsutsikterna. 20 september, 2021
AlzeCure Pharma – Aktiedagen Stockholm, September 7 2021
Strategy Update on Alzheimer’s Disease & NeuroRestore, September 1, 2021
Alzheimer’s disease and the neurotrophins BDNF/NGF by by Prof. Maria Eriksdotter M.D., PhD, Prof, September 1, 2021
Company Overview & Vision by Martin Jönsson CEO, September 1, 2021
NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research, September 1, 2021
Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer, September 1, 2021
Om AlzeCures uppkomst och utveckling – Ett embryo som kan bli något stort –
med Bengt Winblad, professor, senior vid Karolinska Institutet
Om Alzstatin och läkemedel vid Alzheimers sjukdom –
med Bengt Winblad, professor, senior vid Karolinska Institutet”
Om att drabbas av Alzheimers sjukdom, diagnostik, vården idag samt framtida behov –
med Bengt Winblad, professor, senior vid Karolinska Institutet”